Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
Simona DurantiAlessandra FabiMarco FilettiRosa FalconePasquale LombardiGennaro DanieleGianluca FranceschiniLuisa CarbogninAntonella PalazzoGiorgia GarganeseIda ParisGiovanni ScambiaAntonella PietragallaPublished in: Cancers (2021)
Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.
Keyphrases
- clinical trial
- breast cancer risk
- papillary thyroid
- locally advanced
- squamous cell carcinoma
- polycystic ovary syndrome
- squamous cell
- childhood cancer
- small cell lung cancer
- rectal cancer
- neoadjuvant chemotherapy
- pregnancy outcomes
- lymph node metastasis
- adipose tissue
- phase ii
- drug induced
- cardiovascular disease
- coronary artery disease
- lymph node
- drug administration
- skeletal muscle
- phase ii study
- adverse drug
- combination therapy
- pregnant women
- open label